Speaking of Urology: A HIFU expert discusses his treatment criteria

In this episode, Samuel J. Peretsman, MD, describes his background and experience with HIFU as a treatment for patients with prostate cancer, and also discusses his treatment criteria for the modality.

Related Videos

Related Content

Advertisement

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

February 14th 2025

Real-world studies underline safety, efficacy of radium-223 in mCRPC

Benjamin P. Saylor

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

Related Content

Advertisement

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

February 14th 2025

Real-world studies underline safety, efficacy of radium-223 in mCRPC

Benjamin P. Saylor

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.